Provisional agenda

1. Opening of the session

2. Adoption of the agenda and method of work

3. WHO’s role in measures to ensure the availability of good-quality, safe, efficacious and affordable medical products

4. WHO’s role in the prevention and control of medical products of compromised quality, safety and efficacy such as substandard/spurious/falsely-labelled/falsified/counterfeit medical products

5. WHO’s relationship with the International Medical Products Anti-Counterfeiting Taskforce

6. Any remaining issues arising from paragraph 3(d) of decision WHA63(10)

7. Report of the Working Group to the Executive Board at its 130th session